Literature DB >> 9801117

Initial experience using a catheterizable ileovesicostomy (Monti procedure) in children.

M P Cain1, A J Casale, R C Rink.   

Abstract

OBJECTIVES: To present a review of our experience using the recently described Monti ileovesicostomy as an alternative to appendicovesicostomy as a continent catheterizable stoma in children.
METHODS: Between January and December 1997, a Monti ileovesicostomy was performed as part of a reconstructive procedure in 13 children. Mean patient age was 1 1 years, and diagnosis included neurogenic bladder in 11 patients, cloacal exstrophy in 1, and cloacal anomaly in 1 patient. Simultaneous bladder augmentation was performed in 10 children, bladder neck reconstruction or closure in 7, and Malone antegrade continent enema (MACE) in 4.
RESULTS: All 13 patients have continent stomas (100%) and catheterize the Monti ileovesicostomy without difficulty. Mean follow-up was 7 months (range 1 to 14), and there have been no stomal problems or postoperative complications attributed to the ileal channel.
CONCLUSIONS: The Monti ileovesicostomy is a new technique for creation of a continent catheterizable stoma and has allowed preservation of the appendix for the MACE procedure, providing an additional option in patients with an absent or inadequate appendix. Early results of this technique for pediatric reconstruction have been excellent.

Entities:  

Mesh:

Year:  1998        PMID: 9801117     DOI: 10.1016/s0090-4295(98)00301-x

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  2 in total

1.  Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers.

Authors: 
Journal:  J Spinal Cord Med       Date:  2006       Impact factor: 1.985

2.  First case of invasive squamous cell carcinoma in a stoma of a Monti ileovesicostomy.

Authors:  Stephen Reid; Abdulaziz Althunayan; John-Paul Capolicchio; Fadi Brimo; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.